A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body.
A diet that limits meat and dairy but is rich in fruits, vegetables, grains, and nuts is linked to less erectile dysfunction, urinary incontinence, and other common side effects seen in prostate cancer patients, a new study shows.
A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision-making in terms of treatments and side effects for a diverse population.
A study examined the rates of active surveillance use and evaluated the factors associated with selecting this management strategy over surgery or radiation in low-risk prostate cancer, with a focus on underserved Black patients who have been underrepresented in prior studies.Â
The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.
A study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found that Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups—including white or Latino men—despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.
FDA approved Xtandi (enzalutamide) for non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastasis.
An international collaboration led by USC compiled the most comprehensive list of genetic variants associated with prostate cancer risk through a whole-genome analysis that ranks as the largest and most diverse investigation into prostate cancer genetics yet.
In the phase III PSMAfore trial, Pluvicto (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer after treatment with androgen receptor pathway inhibitor therapy, compared to a change in ARPI1.Â
Cedars-Sinai Cancer investigators have identified two new treatment options for men with recurrent prostate cancer—both of which helped patients live longer without their disease progressing than the current standard treatment.Â
